{
  "id": 1507817,
  "title": "EyePoint plummets on pivotal data for main drug",
  "url": "https://urgent.news/2026/08/17/eyepoint-plummets-on-pivotal-data-for-main-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-17T15:31:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/eyepoint-trial-results-durayvu-wet-amd-stock/828022/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}